
Revvity, Inc. – NYSE:RVTY
Revvity stock price today
Revvity stock price monthly change
Revvity stock price quarterly change
Revvity stock price yearly change
Revvity key metrics
Market Cap | 13.47B |
Enterprise value | 15.71B |
P/E | 49.63 |
EV/Sales | 5.77 |
EV/EBITDA | 19.07 |
Price/Sales | 5.00 |
Price/Book | 1.73 |
PEG ratio | 64.03 |
EPS | 1.39 |
Revenue | 2.72B |
EBITDA | 741.09M |
Income | 149.63M |
Revenue Q/Q | -3.69% |
Revenue Y/Y | -9.85% |
Profit margin | 10.18% |
Oper. margin | 11.79% |
Gross margin | 48.8% |
EBIT margin | 11.79% |
EBITDA margin | 27.19% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRevvity stock price history
Revvity stock forecast
Revvity financial statements
$136
Potential upside: 48.76%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 709.06M | 35.55M | 5.01% |
---|---|---|---|
Sep 2023 | 670.73M | 9.49M | 1.42% |
Dec 2023 | 695.90M | 78.56M | 11.29% |
Mar 2024 | 649.92M | 26.01M | 4% |
Payout ratio | 12.47% |
---|
2019 | 0.29% |
---|---|
2020 | 0.19% |
2021 | 0.14% |
2022 | 0.2% |
2023 | 0.25% |
Jun 2023 | 14218549000 | 6.34B | 44.65% |
---|---|---|---|
Sep 2023 | 13421548000 | 5.72B | 42.67% |
Dec 2023 | 13564665000 | 5.69B | 41.96% |
Mar 2024 | 13432705000 | 5.58B | 41.59% |
Jun 2023 | -135.31M | -571.04M | -228.27M |
---|---|---|---|
Sep 2023 | -33.48M | 434.86M | -586.04M |
Dec 2023 | 196.61M | -414.80M | -19.61M |
Mar 2024 | 147.56M | -18.18M | -35.01M |
Revvity alternative data
Sep 2023 | 11,000 |
---|---|
Oct 2023 | 11,000 |
Nov 2023 | 11,000 |
Dec 2023 | 11,000 |
Jan 2024 | 11,000 |
Feb 2024 | 11,000 |
Mar 2024 | 11,500 |
Apr 2024 | 11,500 |
May 2024 | 11,500 |
Jun 2024 | 11,000 |
Jul 2024 | 11,000 |
Revvity other data
Period | Buy | Sel |
---|---|---|
Feb 2024 | 0 | 51589 |
Jun 2024 | 0 | 4000 |
Aug 2024 | 0 | 4350 |
Oct 2024 | 0 | 6461 |
Dec 2024 | 0 | 18365 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | SINGH PRAHLAD R. director, officer.. | Common Stock | 18,365 | $81.29 | $1,492,891 | ||
Sale | SINGH PRAHLAD R. director, officer.. | Common Stock | 15,088 | $116.13 | $1,752,169 | ||
Sale | SINGH PRAHLAD R. director, officer.. | Common Stock | 3,277 | $116.63 | $382,197 | ||
Option | SINGH PRAHLAD R. director, officer.. | NQ Stock Option (right to buy) | 18,365 | $81.29 | $1,492,891 | ||
Sale | VOHRA TAJINDER S officer: Please S.. | Common Stock | 2,134 | $121.72 | $259,750 | ||
Sale | VOHRA TAJINDER S officer: Please S.. | Common Stock | 20 | $122.56 | $2,451 | ||
Sale | VOHRA TAJINDER S officer: Please S.. | Common Stock | 1,661 | $122.47 | $203,423 | ||
Sale | VOHRA TAJINDER S officer: Please S.. | Common Stock | 493 | $122.99 | $60,634 | ||
Sale | VOHRA TAJINDER S officer: Please S.. | Common Stock | 2,053 | $122.04 | $250,548 | ||
Sale | VOHRA TAJINDER S officer: Please S.. | Common Stock | 100 | $123.05 | $12,305 |
Quarter | Transcript |
---|---|
Q1 2024 29 Apr 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 1 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 5 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 6 Aug 2023 | Q2 2023 Earnings Call Transcript |
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy
Safe Biopharma: Revvity's Recurring Revenues And Diagnostics
Lab Instrument Industry Update - New Commercial Entrants
908 Devices: Rare Early-Stage Bioprocess Investment Opportunity
Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Revvity: New Name - But New Investment Outlook? Reiterate Buy
-
What's the price of Revvity stock today?
One share of Revvity stock can currently be purchased for approximately $91.42.
-
When is Revvity's next earnings date?
Unfortunately, Revvity's (RVTY) next earnings date is currently unknown.
-
Does Revvity pay dividends?
Yes, Revvity pays dividends and its trailing 12-month yield is 0.25% with 12% payout ratio. The last Revvity stock dividend of undefined was paid on 6 Sep 2025.
-
How much money does Revvity make?
Revvity has a market capitalization of 13.47B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 16.95% to 2.75B US dollars.
-
What is Revvity's stock symbol?
Revvity, Inc. is traded on the NYSE under the ticker symbol "RVTY".
-
What is Revvity's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Revvity?
Shares of Revvity can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Revvity have?
As Jul 2024, Revvity employs 11,000 workers, which is 4% less then previous quarter.
-
When Revvity went public?
Revvity, Inc. is publicly traded company for more then 60 years since IPO on 6 Jul 1965.
-
What is Revvity's official website?
The official website for Revvity is perkinelmer.com.
-
Where are Revvity's headquarters?
Revvity is headquartered at 940 Winter Street, Waltham, MA.
-
How can i contact Revvity?
Revvity's mailing address is 940 Winter Street, Waltham, MA and company can be reached via phone at +7 816636900.
-
What is Revvity stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Revvity in the last 12 months, the avarage price target is $136. The average price target represents a 48.76% change from the last price of $91.42.
Revvity company profile:

Revvity, Inc.
perkinelmer.comNYSE
11,000
Medical - Diagnostics & Research
Healthcare
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Waltham, MA 02451
CIK: 0000031791
ISIN: US7140461093
CUSIP: 714046109